These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 30192489)

  • 21. Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition.
    Fornai F; Lenzi P; Gesi M; Ferrucci M; Lazzeri G; Busceti CL; Ruffoli R; Soldani P; Ruggieri S; Alessandri MG; Paparelli A
    J Neurosci; 2003 Oct; 23(26):8955-66. PubMed ID: 14523098
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The Kv7/KCNQ channel blocker XE991 protects nigral dopaminergic neurons in the 6-hydroxydopamine rat model of Parkinson's disease.
    Liu H; Jia L; Chen X; Shi L; Xie J
    Brain Res Bull; 2018 Mar; 137():132-139. PubMed ID: 29174294
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Reprint of: revisiting oxidative stress and mitochondrial dysfunction in the pathogenesis of Parkinson disease-resemblance to the effect of amphetamine drugs of abuse.
    Perfeito R; Cunha-Oliveira T; Rego AC
    Free Radic Biol Med; 2013 Sep; 62():186-201. PubMed ID: 23743292
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Activin A protects midbrain neurons in the 6-hydroxydopamine mouse model of Parkinson's disease.
    Stayte S; Rentsch P; Li KM; Vissel B
    PLoS One; 2015; 10(4):e0124325. PubMed ID: 25902062
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [ROLE OF THE INDUCIBLE Hsp70 PROTEIN IN MODULATION OF NEURODEGENERATIVE PATHOLOGY OF NIGROSTRIATAL SYSTEM TYPICAL FOR THE PARKINSON'S DISEASE].
    Ekimova IV; Plaksina DV; Guzhova IV; Meshalkina DA
    Zh Evol Biokhim Fiziol; 2016; 52(1):73-5. PubMed ID: 27220243
    [No Abstract]   [Full Text] [Related]  

  • 26. Succinobucol, a Non-Statin Hypocholesterolemic Drug, Prevents Premotor Symptoms and Nigrostriatal Neurodegeneration in an Experimental Model of Parkinson's Disease.
    Santos DB; Colle D; Moreira EL; Hort MA; Godoi M; Le Douaron G; Braga AL; Assreuy J; Michel PP; Prediger RD; Raisman-Vozari R; Farina M
    Mol Neurobiol; 2017 Mar; 54(2):1513-1530. PubMed ID: 26852411
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mildronate as a regulator of protein expression in a rat model of Parkinson's disease.
    Isajevs S; Isajeva D; Beitnere U; Jansone B; Kalvinsh I; Klusa V
    Medicina (Kaunas); 2011; 47(10):552-9. PubMed ID: 22186119
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Genetic iron chelation protects against proteasome inhibition-induced dopamine neuron degeneration.
    Zhu W; Li X; Xie W; Luo F; Kaur D; Andersen JK; Jankovic J; Le W
    Neurobiol Dis; 2010 Feb; 37(2):307-13. PubMed ID: 19818853
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Chronic dichlorvos exposure: microglial activation, proinflammatory cytokines and damage to nigrostriatal dopaminergic system.
    Binukumar BK; Bal A; Gill KD
    Neuromolecular Med; 2011 Dec; 13(4):251-65. PubMed ID: 21964614
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The pattern of neuronal loss and survival may reflect differential expression of proteasome activators in Parkinson's disease.
    McNaught KS; Jnobaptiste R; Jackson T; Jengelley TA
    Synapse; 2010 Mar; 64(3):241-50. PubMed ID: 19924695
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Elevation of striatal urate in experimental models of Parkinson's disease: a compensatory mechanism triggered by dopaminergic nigrostriatal degeneration?
    De Luca MA; Cauli O; Morelli M; Simola N
    J Neurochem; 2014 Nov; 131(3):284-9. PubMed ID: 24989117
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Experimental modeling of functional deficiency of the nigrostriatal dopaminergic system in mice].
    Kozina EA; Khaindrava VG; Kudrin VS; Kucherianu VG; Klodt PD; Bocharov EV; Raevskiĭ KS; Kryzhanovskiĭ GN; Ugriumov MV
    Ross Fiziol Zh Im I M Sechenova; 2010 Mar; 96(3):270-82. PubMed ID: 20535997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Comparison of the behavioural and histological characteristics of the 6-OHDA and α-synuclein rat models of Parkinson's disease.
    Decressac M; Mattsson B; Björklund A
    Exp Neurol; 2012 May; 235(1):306-15. PubMed ID: 22394547
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multiple molecular pathways are involved in the neuroprotection of GDNF against proteasome inhibitor induced dopamine neuron degeneration in vivo.
    Du Y; Li X; Yang D; Zhang X; Chen S; Huang K; Le W
    Exp Biol Med (Maywood); 2008 Jul; 233(7):881-90. PubMed ID: 18445767
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The nigrostriatal system in the presymptomatic and symptomatic stages in the MPTP monkey model: a PET, histological and biochemical study.
    Blesa J; Pifl C; Sánchez-González MA; Juri C; García-Cabezas MA; Adánez R; Iglesias E; Collantes M; Peñuelas I; Sánchez-Hernández JJ; Rodríguez-Oroz MC; Avendaño C; Hornykiewicz O; Cavada C; Obeso JA
    Neurobiol Dis; 2012 Oct; 48(1):79-91. PubMed ID: 22677034
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Systemic LPS-induced neuroinflammation increases the susceptibility for proteasome inhibition-induced degeneration of the nigrostriatal pathway.
    Deneyer L; Albertini G; Bentea E; Massie A
    Parkinsonism Relat Disord; 2019 Nov; 68():26-32. PubMed ID: 31621614
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease.
    McNaught KS; Perl DP; Brownell AL; Olanow CW
    Ann Neurol; 2004 Jul; 56(1):149-62. PubMed ID: 15236415
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Acetyl-l-carnitine protects dopaminergic nigrostriatal pathway in 6-hydroxydopamine-induced model of Parkinson's disease in the rat.
    Afshin-Majd S; Bashiri K; Kiasalari Z; Baluchnejadmojarad T; Sedaghat R; Roghani M
    Biomed Pharmacother; 2017 May; 89():1-9. PubMed ID: 28199883
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Dietary restriction and 2-deoxyglucose administration improve behavioral outcome and reduce degeneration of dopaminergic neurons in models of Parkinson's disease.
    Duan W; Mattson MP
    J Neurosci Res; 1999 Jul; 57(2):195-206. PubMed ID: 10398297
    [TBL] [Abstract][Full Text] [Related]  

  • 40. How compensation breaks down in Parkinson's disease: Insights from modeling of denervated striatum.
    Navntoft CA; Dreyer JK
    Mov Disord; 2016 Mar; 31(3):280-9. PubMed ID: 26890687
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.